PMID- 29050074
OWN - NLM
STAT- MEDLINE
DCOM- 20190207
LR  - 20190215
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 46
IP  - 10
DP  - 2017 Oct 8
TI  - [Clinicopathologic characteristics and prognosis of neoplastic cell-rich mixed 
      cellularity classic Hodgkin lymphoma].
PG  - 708-713
LID - 10.3760/cma.j.issn.0529-5807.2017.10.010 [doi]
AB  - Objective: To investigate the clinicopathologic characteristics of neoplastic 
      cell-rich mixed cellularity classical Hodgkin lymphoma(MCCHL-R) and to compare 
      the prognosis with typical mixed cellularity classic Hodgkin lymphoma(MCCHL). 
      Methods: Fifty-four patients with MCCHL-R(the tumor cells >10%) and 65 patients 
      with typical MCCHL identified from 1 721 Hodgkin lymphomas were reviewed to 
      compare the clinicopathological characteristics including morphologic and 
      immunophenotypic features, EBV infection status, clinical therapy and overall 
      survival. Results: The median age of the patients of MCCHL-R was 28.5 
      years(range: 9-76 years, maleratiofemale=1.6ratio1.0). Twenty-seven patients(50.0%) had B 
      symptoms. Most patients had cervical lymph node involvement(81.5%, 44/54). 
      Mediastinum and spleen involvement were seen in 69.2%(36/54) and 24.1%(13/54), 
      respectively. Extranodal non-lymphoid organ involvement was seen in 41.3%(19/46) 
      cases. Morphologically, lymph node architectures were effaced at various degree 
      with large neoplastic cells of variable morphology, including 
      Hodgkin/Reed-Sternberg(H/RS) cells and anaplastic large cells. There were 
      abundant background heterogeneous admixtures of non-neoplastic inflammatory and 
      accessory cells that were predominant mature small lymphocytes. All tumors were 
      positive for CD30 and weakly positive for PAX5. Epstein-Barr encoded 
      RNA(EBER)detectable by in situ hybridization was seen in 39.0% cases. Forty-six 
      patients had a median follow-up time of 32.5 months(range: 5-128 months) and the 
      5-year survival rate for stage Ⅰ-Ⅱ and stage Ⅲ-Ⅳ patients were 91.7% and 50.1%, 
      respectively(P<0.05). The 5-year survival rate for MCCHL-R was lower than typical 
      MCCHL patients. Single factor analysis showed that age of >45 years, extranodal 
      involvement and stage Ⅲ-Ⅳ were correlated with poorer 5-year survival 
      rate(P<0.05). Multiple factors Cox proportional hazards regression showed that 
      extranodal involvement was the independent prognostic factor(RR: 4.352, 95%CI: 
      1.122-16.879, P<0.05). Conclusions: MCCHL-R is more common in young people. The 
      tumor has pathological features of classic Hodgkin lymphoma enriched with the 
      tumor cells(>10%) and similar immunophenotype to classical Hodgkin lymphoma. 
      Compared with typical MCCHL, extranodal disease is an independent prognostic 
      factor of MCCHL-R.
FAU - Hou, W H
AU  - Hou WH
AD  - Department of Pathology, 152 Hospital of PLA, Pingdingshan 467000, China.
FAU - Wei, P
AU  - Wei P
AD  - Department of Pathology, Beijing Friendship Hospital, Capital Medical University, 
      Beijing 100050, China.
FAU - Xie, J L
AU  - Xie JL
FAU - Zheng, Y Y
AU  - Zheng YY
FAU - Zhou, X G
AU  - Zhou XG
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
RN  - 0 (Ki-1 Antigen)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Child
MH  - Female
MH  - Herpesvirus 4, Human/genetics
MH  - *Hodgkin Disease/immunology/mortality/pathology/virology
MH  - Humans
MH  - In Situ Hybridization
MH  - Ki-1 Antigen/analysis
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Young Adult
OTO - NOTNLM
OT  - Diagnosis, differential
OT  - Lymphoma, Hodgkin
OT  - Lymphoma, large-cell, anaplastic
OT  - Prognosis
EDAT- 2017/10/21 06:00
MHDA- 2019/02/08 06:00
CRDT- 2017/10/20 06:00
PHST- 2017/10/20 06:00 [entrez]
PHST- 2017/10/21 06:00 [pubmed]
PHST- 2019/02/08 06:00 [medline]
AID - 10.3760/cma.j.issn.0529-5807.2017.10.010 [doi]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2017 Oct 8;46(10):708-713. doi: 
      10.3760/cma.j.issn.0529-5807.2017.10.010.